LAS VEGAS, Aug. 14, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce that a patent application entitled "NEUROSTEROIDS AS MARKERS FOR ALZHEIMER'S DISEASE" has been granted by the European Patent Office (EPO). The patent protects the invention of a quick and simple blood test that is capable of predicting and leading to an early diagnosis of the mind-robbing disease of Alzheimer's. The novel innovation presents DHEA as the biological marker to detect Alzheimer's and other neurodegenerative diseases.
